---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-26-001567"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:22:49.916767+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InMed reports positive INM-901 data in human brain organoid neuroinflammation models

## Summary
- INM-901 reduced neuroinflammation in 3D human brain organoid models of Alzheimer's disease.
- Dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8 observed in two distinct organoid models.
- Company targets pre-IND meeting with FDA in Q3 2026 and Phase 1 trial start in 2027.
- Prior studies showed reduction of inflammatory biomarkers in in vivo Alzheimer's and ex vivo LPS models.
- Studies conducted with Stem Pharm's proprietary neuro-immune organoid platform.

## SEC filing metadata
- accession: 0001062993-26-001567
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000106299326001567/0001062993-26-001567-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000106299326001567/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-26-001567
- JSON: https://secwatch.observer/filing/0001062993-26-001567.json
- Plain text: https://secwatch.observer/filing/0001062993-26-001567.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.